Vor Biopharma Reports $696M Net Loss, Negative Equity, but Secures $75M Private Placement to Extend Runway into Early 2029

summarizeSummary

Vor Biopharma reported a $696.0 million net loss and negative equity for 2025, following a strategic pivot to autoimmune therapies. The company secured a $75.0 million private placement in March 2026, extending its cash runway into early 2029 to support ongoing Phase 3 clinical trials.

check_boxKey Events

• Significant Net Loss and Negative Equity

  The company reported a net loss of $696.0 million for 2025, up from $116.9 million in 2024, and an accumulated deficit of $1.15 billion. Stockholders' equity turned negative, reaching $(164.3) million by year-end 2025.

• Strategic Pivot to Autoimmune Focus

  In June 2025, Vor Biopharma wound down its prior blood cancer programs and in-licensed telitacicept, a novel therapy for autoimmune diseases, incurring a $222.6 million license expense.

• Recent $75M Private Placement

  On March 26, 2026, the company agreed to issue 5,338,078 shares at $14.05 per share, raising $75.0 million in gross proceeds, with closing expected on March 30, 2026. This follows other significant capital raises in 2025.

• Extended Cash Runway

  With existing cash and the proceeds from the March 2026 private placement, the company expects to fund its operations into early 2029.

auto_awesomeAnalysis

Vor Biopharma's annual report reveals a substantial net loss of $696.0 million for 2025, a significant increase from $116.9 million in 2024, and an accumulated deficit of $1.15 billion. The company also reported negative stockholders' equity of $164.3 million as of December 31, 2025, indicating severe financial challenges. However, the filing highlights a critical strategic pivot in June 2025, discontinuing prior blood cancer programs to focus on in-licensed telitacicept for autoimmune diseases. This shift incurred a $222.6 million expense for the telitacicept license and $334.4 million in warrant liabilities. Crucially, the company has been active in capital raising, including a $75.0 million private placement in March 2026, which, combined with other 2025 financings, is expected to fund operations into early 2029. This extended cash runway is vital for a clinical-stage biotech facing significant losses and negative equity, providing a lifeline for its ongoing global Phase 3 trials for telitacicept in generalized Myasthenia Gravis (gMG) and Sjögren's Disease (SjD), which have received Orphan Drug and Fast-Track Designations, respectively.